According to the CDC, 6 in 10 adults in the U.S. have a chronic disease like cancer or diabetes. Meanwhile, the process for discovering new drug treatments is critically expensive and inefficient. About 90% of drug candidates fail to gain FDA approval; the average cost to develop a new drug is over $1 billion; and testing can take over 10 years.
Noam Solomon is on a mission to change this. His company, Immunai, is using artificial intelligence to create an atlas of the human immune system.
